In July 2021, Asia Regenerative Medicine announced the completion of pre-A round funding of tens of millions yuan. This round of funding was led by Sequoia Capital China, followed by Asia Regenerative Medicine's original shareholders.
Llinks, as the legal counsel to this financing round of Sequoia Capital China, provided professional legal services with its rich project experience in the field of investment and financing.
